Histotripsy for Peritoneal Tumour and Lymph Node: a Pilot Study

November 17, 2026 updated by: Albert Chi Yan Chan, The University of Hong Kong

Peritoneal cancer is tricky to be managed. It is not easy to be detected or diagnosed at early stage without symptom, or with common symptoms of many diseases or discomfort and often leads to advance stage at time of diagnosis with few treatment options and limited life span. It is also challenging to handle peritoneal tumour as it usually involves large area in peritoneum, or spread widely throughout the surface of peritoneum if metastatic from other origins. Systemic therapy is the common way to treat peritoneal cacner if the disease is inoperable. However, the unsatisfied penetration rate significantly limits the anti-tumour effect of intraperitoneal chemotherapy even after various attempts and most approaches demonstrated limited efficiency. Effective treatment for peritoneal cancer is still scarce and necessary. While the tumour nature of peritoneal tumour consists of solid tumour and soft tissue tumour, depends on primary or secondary disease, Histotripsy, which can be used on most kinds of solid tumour as well as soft tissue tumour, may yield a new direction and insight on peritoneal cancer management.

Histotripsy is currently indicated for liver tumours, approved by FDA and has been investigated for many disease types in preclinical researches and carried out several clinical trials for liver tumour, benign prostatic hyperplasia, liver tumour combined with systemic therapy, renal tumour, pancreatic tumour, soft tissue tumours, abdominal tumour, calcific aortic valves, and pain in plantar fasciitis, with encouraging results in some clinical trials. As most clinical trials above are for solid tumour and soft tissue tumour that suit the tumour nature of peritoneal tumour, we believe that Histotripsy is also safe and feasible on human with peritoneal tumour. Considering nodal involvement also frequently comes with peritoneal cancer, we would like to conduct an investigation for Histotripsy in peritoneal tumour and lymph node.

Although the result of clinical trial in peritoneal tumour and lymph node are not available yet, HIFU (High Intensity Focused Ultrasound) as another non-invasive ablation also delivered by ultrasound wave which has been in clinical use for many years worldwide can be referenced for Histotripsy. The core difference of HIFU and Histotripsy is, HIFU employs thermal energy to induce coagulative necrosis, while Histotripsy utilises mechanical cavitation to disrupt tumour tissues and preserves adjacent critical structure without the issue of heat, which makes it safer than HIFU. According to some reviews of HIFU, it is obvious that HIFU is feasible and safe without significant adverse event for abdominal tumours including peritoneal tumour and lymph node. Consequently, Histotripsy as a non-thermal ablation and is considered to be safer than HIFU, should also be feasible and safe for peritoneal tumour and lymph node. Hence, it is time for Hong Kong to launch the investigation on the feasibility, safety, and efficacy of Histotripsy in peritoneal tumour and lymph node.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Estimated)

30

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

  • Name: Albert Chan, MBBS, MS
  • Phone Number: +85222553025
  • Email: acchan@hku.hk

Study Locations

      • Hong Kong, Hong Kong, 0000
        • Recruiting
        • The University of Hong Kong
        • Sub-Investigator:
          • Vince Lau, MBBS
        • Contact:
          • Albert Chan, MBBS, MS
          • Phone Number: +85222553025
          • Email: acchan@hku.hk
        • Principal Investigator:
          • Albert Chan, MBBS, MS

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Age ≥ 18 years old

  • Fit for general anaesthesia

  • Peritoneal tumour (eg. intraperitoneal tumour, retroperitoneal tumour) and/or lymph node

  • Size ≤ 10cm for each peritoneal tumour and lymph node

  • With or without distant metastasis

  • Good performance status

    1. Tumour visible and targetable by ultrasound with acceptable acoustic windows
    2. Adequate hematologic, hepatic, and renal function

Exclusion Criteria:

  • Refusal to take part in clinical trial
  • Not fit for general anaesthesia
  • Poor general condition with limited life expectancy
  • Uncontrolled coagulopathy
  • Extensive bowel interposition preventing safe targeting, per recent porcine safety data linking mis-targeting to bowel injury

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Other: Histotripsy

Histotripsy is a promising non-invasive technique that uses high-intensity ultrasound waves to disrupt tissue without damaging surrounding structures

Histotripsy is a promising non-invasive technique that uses high-intensity ultrasound waves to disrupt tissue without damaging surrounding structures. It works by using high-intensity ultrasound waves to create microscopic bubbles within the tumour tissue. These bubbles rapidly expand and collapse, generating shock waves that disrupt the tissue. The technique is highly precise and can be targeted to specific areas of the liver, allowing for selective destruction of tumour cells while minimizing damage to healthy tissue.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
post procedure events
Time Frame: duration of hospital stay, normally 3 days on average

safety monitoring

duration of hospital stay, normally 3 days on average
number of case proceed with Histotripsy
Time Frame: 1 day after procedure

feasibility of doing histotripsy for peritoneal tumour and/or lymph nodes

1 day after procedure
changes in tumour features
Time Frame: up to 3 years

changes in tumour size with serial interval scans

up to 3 years

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Questionnaire based pain assessment
Time Frame: 2 days

to evaluate patient-reported pain level before and after Histotripsy

2 days

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

December 1, 2026

Primary Completion (Estimated)

December 31, 2029

Study Completion (Estimated)

December 31, 2030

Study Registration Dates

First Submitted

September 23, 2026

First Submitted That Met QC Criteria

October 7, 2026

First Posted (Actual)

October 14, 2026

Study Record Updates

Last Update Posted (Actual)

November 18, 2026

Last Update Submitted That Met QC Criteria

November 17, 2026

Last Verified

November 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • GHK-2026-006

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.